Ebstein anomaly (EA) is a rare congenital heart defect (CHD) with a poorly characterized genetic etiology. However, some EA patients carry deletions in 1p36, all of which have been reported to carry distal deletions and share loss of the PRDM16 gene, which is currently considered the most likely candidate for EA development in this region. Here, we report a patient with an 11.96-Mb proximal 1p36 deletion, without loss of PRDM16, who presented with EA and a proximal deletion phenotype. This finding suggests that PRDM16 loss is not required for the development of EA in 1p36 deletions and that the loss of an additional proximal locus in 1p36 is also likely associated with EA. Our data suggest that a distal locus containing the SKI gene and a proximal locus containing the CHD-associated genes RERE and UBE4B are the most probable etiological factors for EA in patients with 1p36 deletion syndrome.

Keywords:
Ebstein anomaly, 1p36 deletion syndrome, PRDM16, RERE, SKI, UBE4B
1.
Arndt AK, Schafer S, Drenckhahn JD, Sabeh MK, Plovie ER, et al: Fine mapping of the 1p36 deletion syndrome identifies mutation of PRDM16 as a cause of cardiomyopathy. Am J Hum Genet 93:67-77 (2013).
2.
Carmignac V, Thevenon J, Adès L, Callewaert B, Julia S, et al: In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet 91:950-957 (2012).
3.
Cunnington RH, Northcott JM, Ghavami S, Filomeno KL, Jahan F, et al: The Ski-Zeb2-Meox2 pathway provides a novel mechanism for regulation of the cardiac myofibroblast phenotype. J Cell Sci 127:40-49 (2014).
4.
Digilio MC, Bernardini L, Lepri F, Giuffrida MG, Guida V, et al: Ebstein anomaly: genetic heterogeneity and association with microdeletions 1p36 and 8p23.1. Am J Med Genet Part A 155A:2196-2202 (2011).
5.
Doyle AJ, Doyle JJ, Bessling SL, Maragh S, Lindsay ME, et al: Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet 44:1249-1254 (2013).
6.
Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, et al: DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet 84:524-533 (2009).
7.
Fregeau B, Kim BJ, Hernández-García A, Jordan VK, Cho MT, et al: De Novo mutations of RERE cause a genetic syndrome with features that overlap those associated with proximal 1p36 deletions. Am J Hum Genet 98:963-970 (2016).
8.
Gajecka M, Mackay KL, Shaffer LG: Monosomy 1p36 deletion syndrome. Am J Med Genet Part C Semin Med Genet 145C:346-356 (2007).
9.
Heilstedt HA, Ballif BC, Howard LA, Kashork CD, Shaffer LG: Population data suggest that deletions of 1p36 are a relatively common chromosome abnormality. Clin Genet 64:310-316 (2003).
10.
Jordan VK, Zaveri HP, Scott DA: 1p36 deletion syndrome: an update. Appl Clin Genet 8:189-200 (2015).
11.
Kaneko-Oshikawa C, Nakagawa T, Yamada M, Yoshikawa H, Matsumoto M, et al: Mammalian E4 is required for cardiac development and maintenance of the nervous system. Mol Cell Biol 25:10953-10964 (2005).
12.
Kang SH, Scheffer A, Ou Z, Li J, Scaglia F, et al: Identification of proximal 1p36 deletions using array-CGH: a possible new syndrome. Clin Genet 72:329-338 (2007).
13.
Kim BJ, Zaveri HP, Shchelochkov OA, Yu Z, Hernández-García A, et al: An allelic series of mice reveals a role for RERE in the development of multiple organs affected in chromosome 1p36 deletions. PLoS One 8:e57460 (2013).
14.
Kuroda K, Han H, Tani S, Tanigaki K, Tun T, et al: Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 18:301-312 (2003).
15.
Mahtab EAF, Vicente-Steijn R, Hahurij ND, Jongbloed MRM, Wisse LJ, et al: Podoplanin deficient mice show a RhoA-related hypoplasia of the sinus venosus myocardium including the sinoatrial node. Dev Dyn 238:183-193 (2009).
16.
Redon R, Rio M, Gregory SG, Cooper RA, Fiegler H, et al: Tiling path resolution mapping of constitutional 1p36 deletions by array-CGH: contiguous gene deletion or “deletion with positional effect” syndrome? J Med Genet 42:166-171 (2005).
17.
Riegel M, Castellan C, Balmer D, Brecevic L, Schinzel A: Terminal deletion, del(1)(p36.3), detected through screening for terminal deletions in patients with unclassified malformation syndromes. Am J Med Genet 82:249-253 (1999).
18.
Saito S, Kawamura R, Kosho T, Shimizu T, Aoyama K, et al: Bilateral perisylvian polymicrogyria, periventricular nodular heterotopia, and left ventricular noncompaction in a girl with 10.5 -11.1 Mb terminal deletion of 1p36. Am J Med Genet A 146:2891-2897 (2008).
19.
Schepers D, Doyle AJ, Oswald G, Sparks E, Myers L, et al: The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen-Goldberg syndrome. Eur J Hum Genet 23:224-228 (2015).
20.
Shimada S, Shimojima K, Okamoto N, Sangu N, Hirasawa K, et al: Microarray analysis of 50 patients reveals the critical chromosomal regions responsible for 1p36 deletion syndrome-related complications. Brain Dev 37:515-526 (2015).
21.
Wu X, Li R, Fu F, Pan M, Han J, et al: Chromosome microarray analysis in the investigation of children with congenital heart disease. BMC Pediatr 17:117 (2017).
22.
Zaveri HP, Beck TF, Hernández-García A, Shelly KE, Montgomery T, et al: Identification of critical regions and candidate genes for cardiovascular malformations and cardiomyopathy associated with deletions of chromosome 1p36. PLoS One 9:e85600 (2014).
23.
Zeglinski MR, Davies JJL, Ghavami S, Rattan SG, Halayko AJ, Dixon IM: Chronic expression of Ski induces apoptosis and represses autophagy in cardiac myofibroblasts. Biochim Biophys Acta 1863:1261-1268 (2016).
24.
Zhu X, Zhang Y, Wang J, Yang JF, Yang YF, Tan ZP: 576 kb deletion in 1p36.33-p36.32 containing SKI is associated with limb malformation, congenital heart disease and epilepsy. Gene 528:352-355 (2013).
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.